Literature DB >> 9565588

Selection of heregulin variants having higher affinity for the ErbB3 receptor by monovalent phage display.

M D Ballinger1, J T Jones, J A Lofgren, W J Fairbrother, R W Akita, M X Sliwkowski, J A Wells.   

Abstract

Heregulins (HRGs) are epidermal growth factor (egf) domain containing polypeptide growth factors that bind and activate several members of the ErbB receptor family. Although HRG can bind to ErbB3 and ErbB4 homodimers, the highest affinity and most intracellularly active receptor complexes are hetero-oligomers containing ErbB2. The HRGbeta egf domain was displayed on the surface of M13 phage to facilitate mutagenic analysis and optimize for binding to a homodimeric ErbB3-immunoglobulin (IgG) fusion. Nine libraries were constructed in which virtually the entire sequence was randomized in stretches of four to six amino acids. These were selected separately for binding to immobilized ErbB3-IgG. Analysis of the resulting sequences revealed some areas that diverged radically from the wild-type, whereas others showed strong conservation. The degree of wild-type conservation correlated strongly with the functional importance of the residues as determined by alanine scanning mutagenesis (Jones, J. T., Ballinger, M. D., Pisacane, P. I., Lofgren, J. A., Fitzpatrick, V. D., Fairbrother, W. J., Wells, J. A., and Sliwkowski, M. X. (1998) J. Biol. Chem. 273, 11667-11674). Some variants from several libraries showed significant improvements in binding affinity to the ErbB3-IgG. These optimized segments were combined in various ways in the same molecule to generate variants (containing up to 16 mutations) that had >50-fold higher affinity than wild-type HRGbeta. The optimized variants stimulated ErbB2 phophorylation on MCF7 cells at levels similar to wild-type. This indicates wild-type affinity is optimized for potency and that factors other than affinity for ErbB3 are limiting. These variants showed enhanced affinity toward the ErbB4 homodimer, suggesting these receptors use very similar binding determinants despite them having 65% sequence identity.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9565588     DOI: 10.1074/jbc.273.19.11675

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  4 in total

1.  Selective targeting and inducible destruction of human cancer cells by retroviruses with envelope proteins bearing short peptide ligands.

Authors:  Timothy J Gollan; Michael R Green
Journal:  J Virol       Date:  2002-04       Impact factor: 5.103

2.  Hot-spot mimicry of a cytokine receptor by a small molecule.

Authors:  Christopher D Thanos; Warren L DeLano; James A Wells
Journal:  Proc Natl Acad Sci U S A       Date:  2006-10-10       Impact factor: 11.205

3.  Erk5 participates in neuregulin signal transduction and is constitutively active in breast cancer cells overexpressing ErbB2.

Authors:  Azucena Esparís-Ogando; Elena Díaz-Rodríguez; Juan Carlos Montero; Laura Yuste; Piero Crespo; Atanasio Pandiella
Journal:  Mol Cell Biol       Date:  2002-01       Impact factor: 4.272

4.  Long-acting antibody ligand mimetics for HER4-selective agonism.

Authors:  Lu Shan; Kimberly M Cook; Nantaporn Haskins; Bilal Omar; Yu Jiang; Andrew Garcia; Adem Koksal; Vaheh Oganesyan; Kim Rosenthal; Herren Wu; William F Dall'Acqua; Melissa M Damschroder
Journal:  Sci Rep       Date:  2020-10-14       Impact factor: 4.379

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.